Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The Company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (PRX003).
May 23, 2016
Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
May 19, 2016
Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress